apnimed – Lab DB

Pharmaceutical R&D

Apnimed Secures Up to $150 Million in Credit Facility to Fuel Potential US Launch of Obstructive Sleep Apnea Therapy AD109

Teuku Ryan Apr 7, 2026 0

Boston, MA – – Apnimed, a clinical-stage biopharmaceutical company focused on developing novel therapies for sleep-related breathing disorders, has announced…

Apnimed Secures Up to $150 Million in Credit Facility to Fuel Potential US Launch of Obstructive Sleep Apnea Therapy AD109

YOU MAY HAVE MISSED

Merck and Moderna’s cancer vaccine is customized for each patient’s tumor

An Unbiased Look at Google Gemini Omni: Features, Costs, and Market Comparison

ESMO 2026: Sacituzumab Tirumotecan Sets New Survival Benchmark in Recurrent Endometrial Cancer

Light-Driven Magnetism Breakthrough Promises Ultrafast, High-Density Digital Data Storage